Press Releases

Date Title
3/31/26 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/25/26 Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
3/24/26 Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
3/19/26 Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
3/16/26 Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
2/27/26 Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
2/26/26 Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
2/25/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
2/24/26 Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
2/24/26 Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/11/26 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
2/4/26 Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
1/26/26 Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
1/23/26 Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
1/12/26 Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
1/7/26 Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
1/5/26 Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference